(Q35185472)

English

Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

based on heuristic

inferred from title

author name string

Yuki Saito

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Risa Oshitanai

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mayako Terao

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mizuho Terada

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Banri Tsuda

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Takuho Okamura

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Yasuhiro Suzuki

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Yutaka Tokuda

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

publication date

2 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Japanese Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1051-1058

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163436

13 July 2018

A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163436

27 September 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163436

27 September 2018

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163436

27 September 2018

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163436

27 September 2018

A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21810868

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://pubmed.ncbi.nlm.nih.gov/21810868

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21810868

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/21810868

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/JJCO/HYR099

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35185472&oldid=1608111776"